A detailed history of Qube Research & Technologies LTD transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Qube Research & Technologies LTD holds 10,034 shares of JANX stock, worth $545,749. This represents 0.0% of its overall portfolio holdings.

Number of Shares
10,034
Holding current value
$545,749
% of portfolio
0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$35.12 - $64.78 $352,394 - $650,002
10,034 New
10,034 $420,000
Q3 2023

Nov 13, 2023

SELL
$9.56 - $14.0 $37,341 - $54,684
-3,906 Reduced 30.9%
8,735 $88,000
Q2 2023

Aug 14, 2023

BUY
$11.08 - $15.92 $140,062 - $201,244
12,641 New
12,641 $150,000
Q3 2021

Nov 12, 2021

SELL
$20.7 - $34.69 $296,196 - $496,379
-14,309 Closed
0 $0
Q2 2021

Aug 13, 2021

BUY
$18.58 - $25.37 $265,861 - $363,019
14,309 New
14,309 $357,000

Others Institutions Holding JANX

About Janux Therapeutics, Inc.


  • Ticker JANX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,663,000
  • Market Cap $2.27B
  • Description
  • Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...
More about JANX
Track This Portfolio

Track Qube Research & Technologies LTD Portfolio

Follow Qube Research & Technologies LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

News

Stay updated on Qube Research & Technologies LTD with notifications on news.